Abstract
Since its first description nearly a decade ago, mammalian target of rapamycin (mTOR) has emerged as a critical regulator of cell size and growth in normal and neoplastic conditions. Many cancers rely on mTOR pathway members for their survival, and these proteins thus form attractive targets with wide potential therapeutic indices. Understanding the role of mTOR in lymphomagenesis is complicated by the intricacy of upstream and downstream components as well as potential differences due to the inherent heterogeneity of lymphoma subtypes. Nevertheless, significant data supports a central role of mTOR pathway in lymphoma. Several lymphoma subtypes harbor PTEN deletions, Akt overexpression, or increased eIF4E. Rapamycin is the prototypical mTOR inhibitor, and has clear anti-tumor effects in many lymphoma preclinical models. Newer rapamycin analogs, including the prodrugs temsirolimus and everolimus, and the non prodrug AP23573, are in clinical trials with preliminary, but promising, activity in hematologic malignancies. The limited treatment options for many patients with relapsed lymphomas coupled with the encouraging activity of mTOR inhibitors warrant ongoing attention and clinical development of these agents.
Keywords: Mammalian TOR (mTOR), Rapamycin, Lymphoma, Lymphomagenesis, PI3 kinase, Akt
Letters in Drug Design & Discovery
Title: mTOR Inhibition in Lymphoma: A Rational and Promising Strategy
Volume: 4 Issue: 3
Author(s): Sonali M. Smith and Koen van Besien
Affiliation:
Keywords: Mammalian TOR (mTOR), Rapamycin, Lymphoma, Lymphomagenesis, PI3 kinase, Akt
Abstract: Since its first description nearly a decade ago, mammalian target of rapamycin (mTOR) has emerged as a critical regulator of cell size and growth in normal and neoplastic conditions. Many cancers rely on mTOR pathway members for their survival, and these proteins thus form attractive targets with wide potential therapeutic indices. Understanding the role of mTOR in lymphomagenesis is complicated by the intricacy of upstream and downstream components as well as potential differences due to the inherent heterogeneity of lymphoma subtypes. Nevertheless, significant data supports a central role of mTOR pathway in lymphoma. Several lymphoma subtypes harbor PTEN deletions, Akt overexpression, or increased eIF4E. Rapamycin is the prototypical mTOR inhibitor, and has clear anti-tumor effects in many lymphoma preclinical models. Newer rapamycin analogs, including the prodrugs temsirolimus and everolimus, and the non prodrug AP23573, are in clinical trials with preliminary, but promising, activity in hematologic malignancies. The limited treatment options for many patients with relapsed lymphomas coupled with the encouraging activity of mTOR inhibitors warrant ongoing attention and clinical development of these agents.
Export Options
About this article
Cite this article as:
Smith M. Sonali and van Besien Koen, mTOR Inhibition in Lymphoma: A Rational and Promising Strategy, Letters in Drug Design & Discovery 2007; 4 (3) . https://dx.doi.org/10.2174/157018007780077435
DOI https://dx.doi.org/10.2174/157018007780077435 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Systemic Fungal Infections Caused by Aspergillus Species: Epidemiology, Infection Process and Virulence Determinants
Current Drug Targets Drug-Induced Peripheral Neuropathy: Diagnosis and Management
Current Cancer Drug Targets Diverse Mechanisms of AKT Pathway Activation in Human Malignancy
Current Cancer Drug Targets Novel Drugs for Chronic Lymphoid Leukemias: Mechanism of Action and Therapeutic Activity
Current Medicinal Chemistry The Current and Future Therapies for Human Osteosarcoma
Current Cancer Therapy Reviews Stromal Cell Derived Factor-1 / CXCL12, CXCR4 and CD26 in the Mobilization and Homing of Hematopoietic Stem and Progenitor Cells
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Therapeutic Potential of Targeting PAK Signaling
Anti-Cancer Agents in Medicinal Chemistry Target Therapies in Pancreatic Carcinoma
Current Medicinal Chemistry To Cardiovascular Disease and Beyond: New Therapeutic Perspectives of Statins in Autoimmune Diseases and Cancer
Current Drug Targets Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers
Current Pharmaceutical Design CD248: Reviewing its Role in Health and Disease
Current Drug Targets Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity
Current Drug Delivery Immunomodulatory Drugs (IMiDs™): A New Treatment Option for Myelodysplastic Syndromes
Current Pharmaceutical Biotechnology Inflammation and Anemia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeting Ion Channels in Leukemias: A New Challenge for Treatment
Current Medicinal Chemistry Discovery of Multi-target Anticancer Agents Based on HDAC Inhibitor MS-275 and 5-FU
Medicinal Chemistry Ofatumumab: A Novel Anti-CD20 Monoclonal Antibody for the Treatment of Chronic Lymphocytic Leukemia
Current Drug Therapy CYP Epoxygenase Derived EETs: From Cardiovascular Protection to Human Cancer Therapy
Current Topics in Medicinal Chemistry Exploring the Binding Affinity of Novel Syringic Acid Analogues and Critical Determinants of Selectivity as Potent Proteasome Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Interstitial Lung Disease in Systemic Lupus Erythematosus, Sjogren’s Syndrome, and Mixed Connective Tissue Disease
Current Respiratory Medicine Reviews